AS-075 Long-Term Effects of Varying Alcohol Dosing in Percutaneous Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: A Randomized Study

2012 ◽  
Vol 109 (7) ◽  
pp. S2
Author(s):  
Josef Veselka ◽  
David Zemanek ◽  
Pavol Tomasov ◽  
Jakub Honek
2005 ◽  
Vol 46 (3) ◽  
pp. 470-476 ◽  
Author(s):  
Steve R. Ommen ◽  
Barry J. Maron ◽  
Iacopo Olivotto ◽  
Martin S. Maron ◽  
Franco Cecchi ◽  
...  

2018 ◽  
Vol 19 ◽  
pp. e76-00
Author(s):  
G. Saitto ◽  
F. Grimaldi ◽  
A. Varrica ◽  
A. Biondi ◽  
A. Garatti ◽  
...  

2003 ◽  
Vol 41 (6) ◽  
pp. 146
Author(s):  
Maria J. Eriksson ◽  
Anna Woo ◽  
E. Douglas Wigle ◽  
David Focsaneanu ◽  
Paul Rakowski ◽  
...  

2018 ◽  
Vol 2018 (3) ◽  
Author(s):  
Juan José Santos Mateo ◽  
Juan R Gimeno

Alcohol septal ablation (ASA) has become an alternative to surgical myectomy in obstructive hypertrophic cardiomyopathy since it was first introduced in 1994 by Sigwart. The procedure alleviates symptoms by producing a limited infarction of the upper interventricular septum, resulting in a decrease in left ventricular outflow tract (LVOT) gradient. The technique has been improved over time and the results are comparable with those of myectomy. Initial concerns about long-term outcomes have been largely resolved. In this review, we discuss indications, technical aspects, clinical results and patient selection to ASA.


Sign in / Sign up

Export Citation Format

Share Document